Company news

Share this article:
Pfizer has announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the US new drug application and the European marketing authorization application.
 
Generic manufacturer Mylan will not sell Dey L.P., its specialty pharmaceutical division. After a review, the company decided Dey L.P. would be positive for earnings through 2010.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions